NCT06983821 - Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2029

Conditions

Granulomatosis With PolyangiitisMicroscopic Polyangiitis (MPA)

Interventions

DRUG

Cyclophosphamide

IV Cyclophosphamide 15mg/kg/dose (age and eGFR adjusted), 2 doses 2 weeks apart

DRUG

Standard of Care (SOC)

Participants will receive standard of care induction agent and glucocorticoid taper, at investigator discretion

DRUG

Prednisone

4 weeks prednisone taper

DRUG

Rituximab (R)

Rituximab infusions, dosing and schedule at clinician/investigator discretion

Trial Locations (2)

St-Joseph's Hospital, Hamilton

The Ottawa Hospital, Ottawa